Lacidipine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Lacidipine: From Hypertension (Calcium Channel Blocker) to Migraine Disorder
One-Sentence Summary
Lacidipine is a lipophilic dihydropyridine L-type calcium channel blocker with vascular selectivity. The Singapore license data compiled for this report do not list an approved indication. The TxGNN model predicts it may be effective for migraine disorder, but there are currently 0 clinical trials and 0 publications directly supporting this prediction. It rests on model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore license data (the drug class is used for hypertension) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 98.34% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Based on known information, lacidipine is a dihydropyridine L-type calcium channel blocker that relaxes blood vessels and has vascular selectivity. Its efficacy as a class in vascular conditions is well established, so it may be mechanistically applicable to migraine.
Calcium channel modulation is biologically plausible in migraine. Another calcium channel blocker, flunarizine, is used for migraine prophylaxis. However, no trials or literature on lacidipine in migraine were retrieved, so the prediction currently reflects a class-level hypothesis, not lacidipine-specific proof.
Other predicted indications (for reference)
| Predicted Indication | Score | Evidence Level | Comment |
|---|---|---|---|
| Nephrogenic syndrome of inappropriate antidiuresis | 98.20% | L5 | No clear mechanistic link; likely a network-level association |
| Migraine with brainstem aura | 98.07% | L5 | Subtype of migraine; same rationale as migraine |
| Pulmonary hypertension | 97.89% | L4 | Plausible mechanism, but the retrieved papers are indirect |
| Kyphoscoliotic heart disease | 97.61% | L5 | Speculative link via pulmonary vascular pressure |
| Alopecia | 97.37% | L5 | Weak, unsupported link |
| Prinzmetal angina | 97.33% | L4 | Calcium channel blockers are standard therapy for the class; no lacidipine-specific data |
| Raynaud disease | 97.28% | L4 | Strong class-level rationale; the best candidate for follow-up (research question) |
| Hypotrichosis simplex of the scalp | 97.13% | L5 | No mechanistic link |
| Congenital hypotrichosis milia | 96.90% | L5 | No mechanistic link |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for migraine disorder.
For reference, a few publications were retrieved for other predicted indications. They are indirect and none is specific to lacidipine:
| PMID | Year | Type | Journal | Related Indication | Key Findings |
|---|---|---|---|---|---|
| 14689111 | 2003 | Review | Herz | Prinzmetal angina | General review of differential therapy with calcium antagonists |
| 9471233 | 1997 | Review | Investigacion clinica | Pulmonary hypertension | Review of calcium antagonist actions and their role in arterial hypertension |
| 8973777 | 1996 | Review/Commentary | Blood pressure. Supplement | Pulmonary hypertension | Commentary on hypertension and atherosclerosis, based on the MIDAS study (isradipine) |
| 32337731 | 2020 | Pharmacovigilance study | British journal of clinical pharmacology | Raynaud disease; pulmonary hypertension | WHO pharmacovigilance signal matching generated drug-repurposing hypotheses for Raynaud's phenomenon |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN07934P | LACIPIL TABLET 4 mg | Tablet, film coated | Not stated in the license data |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The migraine prediction has a high model score (98.34%) and a plausible class-level mechanism, but no lacidipine-specific trials or publications support it (Evidence Level L5). Safety information has not been obtained, so the candidate cannot yet move to safety screening.
To proceed, the following is needed:
- The Singapore package insert (warnings, contraindications, approved indication), which is a blocking gap
- Mechanism of action data for lacidipine
- Literature and trial searches specific to lacidipine in migraine, and a comparison with flunarizine
- Consider prioritising Raynaud disease or Prinzmetal angina, where the class-level rationale is stronger, as an alternative or parallel direction
- Confirmation of route and dosage-form compatibility (oral film-coated tablet only is currently registered)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.